← Back

$ Value

$0

Shares

3,408

Price

$0

Filed

Apr 1

Insider

Name

Tezel Ahmet

Title

Chief Innovation Officer

CIK

0002023439

Roles

Officer

Transaction Details

Transaction Date

2026-03-30

Code

M

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

6,814

Footnotes

Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. | Shares withheld to satisfy tax liability. | Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. | On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement. | On March 30, 2026, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2027. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement. | Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. | On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's revenue growth for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. | On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2026 and ending December 31, 2028 relative to the total shareholder return of an index of companies, as determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. | On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's adjusted earnings per share (EPS) for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.

Filing Info

Accession No.

0001639691-26-000027

Form Type

4

Issuer CIK

0001639691

Tezel Ahmet's History

Date Ticker Type Value
2026-03-30 LIVN M $0
2026-03-30 LIVN F $73K
2026-03-30 LIVN M $0
2026-03-30 LIVN A $0
2026-03-30 LIVN A $0
2026-03-30 LIVN A $0
2026-03-30 LIVN A $0
2025-06-15 LIVN M $0
2025-06-15 LIVN F $47K
2025-06-15 LIVN M $0

Other Insiders at LIVN (90d)

Insider Bought Sold Last
Shvartsburg Alex
Chief Financial Officer
2026-03-30
Bolton Stephanie
President, Global Epilepsy
2026-03-30
Makatsaria Vladimir
Chief Executive Officer
2026-03-30
Tezel Ahmet
Chief Innovation Officer
2026-03-30
Poletti Franco
President, Cardiopulmonary
2026-03-30
Kozmina Natalia
Chief Human Resources Officer
2026-03-30